For the topical management of plaque psoriasis, the new fixed dose combination of betamethasone dipropionate (BDP) and calcipotriol (CAL) cream based on PAD Technology (CAL/BDP PAD-cream) provides superior efficacy, enhanced patient quality of life, and equivalent favorable safety when compared to the currently marketed CAL/BDP topical suspension/gel [CAL/BDP TS], says a study published in The Journal of the European Academy of Dermatology and Venereology.

In this study, the data from two phase III,  randomized, multicenter, investigator-blind, active, and vehicle-controlled trials that recruited psoriasis people were pooled and evaluated. Investigational products included CAL/BDP PAD-cream designed for higher skin penetration and better patient preference, an active control (CAL/BDP TS), and a cream vehicle, that were applied once daily for eight weeks.

Both CAL/BDP PAD-cream and CAL/BDP TS were compared in terms of quality of life, safety,  and efficacy. For mitigating psoriasis, the new CAL/BDP PAD-cream formulation showed superior efficacy and safety following eight weeks of therapy. Compared to the CAL/BDP TS group, the  CAL/BDP PAD-cream group exhibited higher values for physician global assessment (PGA) therapeutic success, mean percent decline in modified Psoriasis Area and Severity Index (mPASI), and Dermatology Life Quality Index (DLQI) 0/1, as shown in Table 1:

There were no CAL/BDP PAD-cream-elicited adverse drug reactions with a frequency of >1%. Thus, CAL/BDP PAD-cream is better than CAL/BDP TS for the management of plaque psoriasis.